Clin2
NCT07758231Possibly a fitNot yet recruiting

How tirzepatide affects alcohol processing

GLP-1Alcohol

This study looks at how the diabetes medication tirzepatide affects the way your body processes alcohol. It may help us understand if this drug changes how alcohol affects you.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
5 people
Ages
21 years to 55 years
Study type
Interventional

Who can take part

  • You are between 21 and 55 years old.
  • Your body mass index (BMI) is between 30 and 45.
  • You have been taking a stable dose of branded tirzepatide for at least 4 weeks.
  • You regularly drink alcohol.
  • You are in good mental and physical health, with no major medical conditions.
  • You have a valid driver's license and at least 2 years of driving experience.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06994338Recruiting· Phase 2
Tirzepatide for alcohol use disorder

This study tests whether a medication called tirzepatide (a once-weekly injection) can help people reduce their alcohol consumption. It is for people who drink heavily, have a high BMI, and are actively seeking help to drink less.

Los Angeles, California
NCT06811324Recruiting· Phase 2
Tirzepatide for muscle and vessel health in older adults

This study tests if the drug tirzepatide can improve muscle and blood vessel health in older adults with obesity. You may be eligible if you are 50 or older, have a BMI between 30 and 40, and do not have diabetes.

San Antonio, Texas
NCT07046819Recruiting· Phase 2
Tirzepatide for liver disease linked to alcohol use

This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.

Bethesda, Maryland
NCT06939088Recruiting· Phase 2
Tirzepatide for alcohol reduction in schizophrenia

This trial tests if tirzepatide, a once-weekly injection, can help reduce heavy drinking in people who have both schizophrenia and alcohol use disorder. If you struggle with alcohol and have stable schizophrenia, this study may offer a new treatment option.

Aalborg, Denmark
NCT06727331Recruiting· Phase 2
Tirzepatide for alcohol use recovery

This trial tests if tirzepatide, a medication that helps with appetite and blood sugar, can help people with alcohol use disorder drink less or stop drinking. You would visit the clinic regularly and receive the drug or a placebo.

Boston, Massachusetts
NCT07292519Not yet recruiting· Phase 2
Tirzepatide and counseling for alcohol use and weight

This study tests whether a weekly injection of tirzepatide (a medicine for weight and blood sugar) combined with cognitive-behavioral therapy (counseling) can help people with alcohol use disorder who are also overweight or obese. By reducing alcohol cravings and supporting weight loss, the treatment aims to improve both drinking and health outcomes.

Sydney, New South Wales

Hear when a new GLP-1 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.